Chad Robins, CEO & Co-Founder, emphasized "another quarter of strong execution and accelerating momentum across the business," highlighting meaningful wins in profitability and growth for the MRD ...

Multiple insider sales by senior executives at Adaptive Biotechnologies (NasdaqGS:ADPT) were disclosed following the company’s strong quarterly results. The CEO and Chief Scientific Officer reported ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the best hot stocks under $20 to buy. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) received several bullish rating updates following ...

Adaptive reported preliminary, unaudited revenue of approximately $72 million for the fourth quarter of 2025, representing a 51% increase compared to the same period in 2024. Full-year 2025 revenue ...

CEO Chad Robins told investors at the 46th Annual TD Cowen Healthcare Conference that the company is looking to build on what he described as strong recent performance in minimal residual disease (MRD ...

CEO Chad Robins highlighted a strong start to the year, with MRD revenue increasing 34% year-over-year, driven by clinical volumes, ASP improvements, and pharma sequencing. The company received its ...

Adaptive Biotechnologies Corporation announced it will release its second quarter 2025 financial results on August 5, 2025, after market close, followed by a conference call at 1:30 p.m. Pacific Time.

Adaptive Biotechnologies reported a 42% revenue increase in its MRD segment, with a focus on achieving profitability in 2025. Adaptive Biotechnologies Corporation reported its financial results for ...

SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...

The MarketWatch News Department was not involved in the creation of this content. A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data ...

The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. The commercial-stage Adaptive booked $58.9 ...